Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 260 clinical trials
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient perspective in

bedaquiline
pretomanid
moxifloxacin
clofazimine
linezolid
  • 0 views
  • 26 Jan, 2021
  • 6 locations
Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic T Cells

Brief summary: Allogeneic T cells from healthy donor will be administrated intravenously to patients with the MDR-TBand then the safety and efficacy of T cells will be evaluated.

  • 0 views
  • 22 Jan, 2021
  • 1 location
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

sensitivity for 24 to 36 weeks in subjects with fluoroquinolone-resistant MDR-TB .

  • 0 views
  • 29 Jan, 2021
  • 13 locations
BCG and Plasma Amyloid in Non-Demented Adults

BCG vaccination, the most widely used vaccination in the world, is used to reduce risk of tuberculosis infection; it is used for other mycobacterial infections as well, benefiting leprosy and

  • 0 views
  • 03 Feb, 2021
  • 1 location
Tuberculosis (TB) Aftermath

TB Aftermath will compare effectiveness, cost-effectiveness and feasibility of two ACF strategies that are presently being considered by the RNTCP for detecting recurrent TB and provide evidence

  • 0 views
  • 05 Mar, 2021
  • 1 location
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The

  • 0 views
  • 25 Jan, 2021
  • 16 locations
Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals

Early diagnosis can contribute to good treatment outcomes and isolate infection control.

  • 4 views
  • 25 Jan, 2021
  • 4 locations
N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy

Biliary atresia (BA) is a devastating liver disease of infancy, characterized by bile duct obstruction leading to liver fibrosis, cirrhosis, and eventual need for transplantation in most cases. BA is treated with Kasai portoenterostomy (KP). KPs can achieve bile drainage and improve outcomes. However, even with standard evidence of "good …

  • 1 views
  • 30 Jan, 2021
  • 1 location
Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease

A prospective, single-center, single-blinded study involving patients with refractory nontuberculous mycobacteria lung disease to ascertain pharmacokinetics, safety, efficacy, and tolerability of two dose levels of parenteral administration of recombinant Interleukin-7 (IL-7) (CYT107).

  • 0 views
  • 22 Feb, 2021
  • 1 location
AGILE (Early Phase Platform Trial for COVID-19)

The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one master protocol ensures different candidates …

  • 0 views
  • 19 Feb, 2021
  • 1 location